Stay updated on Nivolumab in Relapsed/Refractory DLBCL Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in Relapsed/Refractory DLBCL Clinical Trial page.

Latest updates to the Nivolumab in Relapsed/Refractory DLBCL Clinical Trial page
- Check4 days agoChange DetectedThe page’s displayed software/API version indicator was updated from **v3.5.2** to **v3.5.3**, reflecting a general site release rather than any study detail change.SummaryDifference0.0%

- Check12 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check40 days agoChange DetectedUpdated the Italy location from Napoli to Naples (Naples, Italy, 80131) and added Naples, Italy, 80131 as a location. The page revision was updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check54 days agoChange DetectedRevision: v3.4.3.SummaryDifference0.0%

- Check76 days agoChange Detected- Site revision updated from v3.4.1 to v3.4.2. No study content or user-facing details were changed.SummaryDifference0.0%

- Check84 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 on the page.SummaryDifference0.0%

Stay in the know with updates to Nivolumab in Relapsed/Refractory DLBCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in Relapsed/Refractory DLBCL Clinical Trial page.